Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience

被引：0
|
作者：
Bose, Subhadeep [1 ]
Khaja, Mujtaba Syed [1 ]
Siva, Asha [1 ]
Wilson, Paula [1 ]
Grist, Helen [1 ]
Murukesh, Nishanth [1 ]
机构：
[1] Worcestershire Acute Hosp NHS Trust, Worcester, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21091
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction
    Tokaca, N.
    O'Brien, M.
    Bhosle, J.
    Yousaf, N.
    Kumar, R.
    Popat, S.
    Walder, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S89 - S90
  • [42] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
    Liu, Qiao
    Zhou, Zhen
    Luo, Xia
    Yi, Lidan
    Peng, Liubao
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [43] Lipid lowering with inclisiran: a real-world single-centre experience
    Padam, Pritpal
    Barton, Lucy
    Wilson, Stewart
    David, Alessia
    Walji, Shahenaz
    de Lorenzo, Ferruccio
    Ray, Kausik K.
    Jones, Ben
    Cegla, Jaimini
    OPEN HEART, 2022, 9 (02):
  • [44] Sacubitril-Valsartan: real-world single-centre experience
    Climent, Herminio Morillas
    Lopez, Alvaro Vicedo
    Moya, Julia Seller
    Torres, Edgard Alania
    Jornet, Emilio Galcera
    Rodriguez, Ainhoa Larumbe
    Piles, Carlos Nunez
    Munoz, Alfonso Valle
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 257 - 257
  • [45] Real-world evidence of first-line cetuximab (CX) plus paclitaxel (PX) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Cirauqui Cirauqui, B.
    Martinez Trufero, J.
    Plana Serrahima, M.
    Garcia Castano, A.
    Rubio-Casadevall, J.
    Carral Maseda, A.
    Iglesias Docampo, L.
    Perez Segura, P.
    Ceballos Lenza, I.
    Gutierrez Calderon, V.
    Fuster Salva, J.
    Pena Alvarez, C.
    Arrazubi Arrula, V.
    del Barco Morillo, E.
    Chaves Conde, M.
    Martinez Galan, J.
    Duran Sanchez, M.
    Quiroga, V.
    Ortega, E.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S852 - S853
  • [46] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
    Zhang, H.
    Cun, F. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
  • [47] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Prevalence, Onset, and Severity of Renal Impairment With Pemetrexed/Carboplatin plus /- Pembrolizumab in Metastatic Non-Squamous NSCLC
    Miller, J.
    Brown, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1084 - S1084
  • [49] LEAP-014: first-line lenvatinib plus pembrolizumab plus chemotherapy in advanced/metastatic esophageal squamous cell carcinoma
    Sun, Jong-Mu
    Adenis, Antoine
    C Enzinger, Peter
    Shah, Manish A.
    Kato, Ken
    Bennouna, Jaafar
    Doi, Toshihiko
    Hawk, Natalyn Nicole
    Yu, Li
    Shah, Sukrut
    Bhagia, Pooja
    Shen, Lin
    FUTURE ONCOLOGY, 2024,
  • [50] First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation
    Yanjuan Xiong
    Lu Wang
    Weihong Zhang
    Yuan Meng
    Yang Wang
    Meng Shen
    Li Zhou
    Runmei Li
    Yingge Lv
    Shengguang Wang
    Xiubao Ren
    Liang Liu
    BMC Cancer, 24 (1)
12345